We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

104 hedge funds and large institutions have $1.1B invested in Theravance Biopharma in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 12

67% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 21

8% more funds holding

Funds holding: 96 → 104 (+8)

0.33% more ownership

Funds ownership: 86.07% → 86.4% (+0.33%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

10% less capital invested

Capital invested by funds: $1.22B → $1.1B (-$121M)

98% less call options, than puts

Call options by funds: $220K | Put options by funds: $13.3M

Holders
104
Holders Change
+8
Holders Change %
+8.33%
% of All Funds
2.25%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
35
Reduced
21
Closed
12
Calls
$220K
Puts
$13.3M
Net Calls
-$13M
Net Calls Change
-$13.3M

Top Buyers

1
WIM
Woodford Investment Management
United Kingdom
+$27M
2
FI
Fosun International
China
+$2.65M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$2.39M
4
JG
Jefferies Group
New York
+$2.32M
5
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$2.05M

Top Sellers

1
CAM
Cormorant Asset Management
Massachusetts
-$22.6M
2
BlackRock
BlackRock
New York
-$3.71M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$2.58M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.02M
5
UBS Group
UBS Group
Switzerland
-$622K
Name Holding Trade Value Shares
Change 		Change in
Stake
WIM
1
Woodford Investment Management
United Kingdom
$303M +$27M +1,063,450 +9%
BG
2
Baupost Group
Massachusetts
$211M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$186M +$640K +25,234 +0.3%
Vanguard Group
4
Vanguard Group
Pennsylvania
$87.9M -$2.58M -101,835 -3%
BlackRock
5
BlackRock
New York
$84.3M -$3.71M -146,403 -4%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$27.5M -$560K -22,083 -2%
State Street
7
State Street
Massachusetts
$20.5M +$561K +22,108 +3%
Norges Bank
8
Norges Bank
Norway
$19.9M – – –
Morgan Stanley
9
Morgan Stanley
New York
$15.6M +$1.55M +61,241 +10%
Northern Trust
10
Northern Trust
Illinois
$12.5M -$18.1K -714 -0.1%
RSCM
11
Rock Springs Capital Management
Maryland
$12.5M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$12.3M +$1.19M +46,805 +9%
C
13
Chescapmanager
Maryland
$10.2M +$861K +33,943 +8%
CS
14
Candriam SCA
Luxembourg
$6.34M – – –
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
$6.09M +$2.39M +94,070 +54%
Goldman Sachs
16
Goldman Sachs
New York
$6.03M +$788K +31,071 +13%
State of New Jersey Common Pension Fund D
17
State of New Jersey Common Pension Fund D
New Jersey
$6.02M – – –
Charles Schwab
18
Charles Schwab
California
$5.42M +$103K +4,070 +2%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$4.74M +$27.7K +1,092 +0.5%
JP Morgan Chase
20
JP Morgan Chase
New York
$4.53M +$1.54M +60,700 +44%
TCIM
21
TIAA CREF Investment Management
New York
$3.85M +$64.4K +2,539 +2%
TA
22
Teachers Advisors
New York
$3.53M +$48.7K +1,921 +1%
Wells Fargo
23
Wells Fargo
California
$3.41M +$478K +18,859 +14%
FI
24
Fosun International
China
$2.39M +$2.65M +104,465 New
OWIM
25
Old West Investment Management
California
$2.26M -$261K -10,312 -9%
1
2 3 4 5

TBPH Hedge Fund Activity: Q1 2019 in Review

104 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q1 2019, worth a combined $1.1B — down 9.9% from $1.22B a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new TBPH positions and 12 closed out — a net gain of 8 holders — while 35 added to existing stakes and 21 trimmed.

The largest buyer was Woodford Investment Management, adding an estimated $27M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $22.6M sold.

  • 104 institutional investors held Theravance Biopharma (TBPH) as of Q1 2019, up from 96 in Q4 2018.
  • Funds reported $1.1B of Theravance Biopharma stock for Q1 2019, down 9.9% quarter-over-quarter.
  • 20 funds opened new Theravance Biopharma positions in Q1 2019 and 12 closed out, a net change of +8 holders.
  • The largest Theravance Biopharma buyer in Q1 2019 was Woodford Investment Management, an estimated $27M added.
  • The largest Theravance Biopharma seller in Q1 2019 was Cormorant Asset Management, an estimated $22.6M sold.

Based on aggregated 13F filings for Q1 2019.